{
  "pmcid": "4486927",
  "config": {
    "model": "gemini",
    "strategy": "few-shot"
  },
  "usage": {
    "input": 17914,
    "output": 758
  },
  "raw_text": "```json\n{\n  \"extractions\": [\n    {\n      \"outcome\": \"The SVR rates if the patients had IL-28B rs8099917 TT genotype, and GT/GG genotype\",\n      \"intervention\": \"peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks\",\n      \"comparator\": \"peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks\",\n      \"outcome_type\": \"binary\",\n      \"intervention_events\": 17,\n      \"intervention_group_size\": 23,\n      \"comparator_events\": 2,\n      \"comparator_group_size\": 24,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"The early virologic response (EVR)\",\n      \"intervention\": \"peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks\",\n      \"comparator\": \"peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks\",\n      \"outcome_type\": \"binary\",\n      \"intervention_events\": 86,\n      \"intervention_group_size\": 94,\n      \"comparator_events\": 82,\n      \"comparator_group_size\": 93,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"the end-of-treatment virologic response\",\n      \"intervention\": \"peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks\",\n      \"comparator\": \"peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks\",\n      \"outcome_type\": \"binary\",\n      \"intervention_events\": 83,\n      \"intervention_group_size\": 94,\n      \"comparator_events\": 75,\n      \"comparator_group_size\": 93,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"The SVR rates when the patients had BMI >30 kg/m2\",\n      \"intervention\": \"peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks\",\n      \"comparator\": \"peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks\",\n      \"outcome_type\": \"binary\",\n      \"intervention_events\": 10,\n      \"intervention_group_size\": 19,\n      \"comparator_events\": 6,\n      \"comparator_group_size\": 12,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    }\n  ]\n}\n```",
  "extraction": [
    {
      "outcome": "The SVR rates if the patients had IL-28B rs8099917 TT genotype, and GT/GG genotype",
      "intervention": "peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks",
      "comparator": "peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks",
      "outcome_type": "binary",
      "intervention_events": 17,
      "intervention_group_size": 23,
      "comparator_events": 2,
      "comparator_group_size": 24,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "4486927"
    },
    {
      "outcome": "The early virologic response (EVR)",
      "intervention": "peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks",
      "comparator": "peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks",
      "outcome_type": "binary",
      "intervention_events": 86,
      "intervention_group_size": 94,
      "comparator_events": 82,
      "comparator_group_size": 93,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "4486927"
    },
    {
      "outcome": "the end-of-treatment virologic response",
      "intervention": "peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks",
      "comparator": "peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks",
      "outcome_type": "binary",
      "intervention_events": 83,
      "intervention_group_size": 94,
      "comparator_events": 75,
      "comparator_group_size": 93,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "4486927"
    },
    {
      "outcome": "The SVR rates when the patients had BMI >30 kg/m2",
      "intervention": "peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks",
      "comparator": "peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks",
      "outcome_type": "binary",
      "intervention_events": 10,
      "intervention_group_size": 19,
      "comparator_events": 6,
      "comparator_group_size": 12,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "4486927"
    }
  ]
}